Journey Medical Corp.

The most unusual aspect of the dozen applications with September 2023 goal dates at the US FDA is how unusual they aren’t. Standard reviews are the rule, even for the lone breakthrough therapy-designa

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Hasten Gets Greater China Rights T

Journey Medical Corp. ’s DFD-29, partnered with Dr. Reddy's Laboratories Ltd. , has potential to claim a significant share of the papulopustular rosacea market, which Galderma S.A. ’s Oracea (doxycy

Roche Holding AG , Genentech, Inc. and their affiliated companies were the busiest deal makers in the biopharmaceutical sector for the second consecutive year in 2021, with 23 deals across all cate